Home » Research » Clinical Trials
Clinical Trials
An important part of the journey to a cure is to have research thoroughly tested and trialled prior to gaining approval for human use. JDRF currently has a number of therapies at this stage of development.
Islet Transplantation Program (ITP)
The Australian Islet Transplantation Program (ITP) aims to replace islet cells lost through type 1 diabetes by isolating healthy cells from a donor pancreas and infusing them into a recipient, thus restoring the body's ability to produce its own insulin.
The ITP in Australia is funded by the Australian Department of Health and Ageing and managed by JDRF.
For more information please see the Australian Islet Transplantation Program website
Type 1 Diabetes Prevention Study (IntraNasal Insulin Trial - INIT II)
This trial is investigating the effectiveness of an inhalable vaccine in preventing the onset of type 1 diabetes in high risk individuals.
The vaccine works by teaching the immune system to protect the insulin-producing cells in the pancreas, rather than attacking them and triggering the development of type 1 diabetes.
If you are interested in finding out more about this world-leading research and potentially participating in the trial, please visit the Type 1 Diabetes Prevention Study website or call 1300 138 712.
TrialNet
The Type 1 Diabetes TrialNet Study Group is an international group of investigators that are dedicated to testing new approaches in the prevention and treatment of type 1 diabetes.
Relatives of people with type 1 diabetes have about a three to four percent chance of testing positive for anti-bodies associated with diabetes. TrialNet will identify adults and children at risk for developing diabetes by testing for the presence of these antibodies in the blood.
Those at risk for developing the disease may be able to join the TrialNet clinical trial.
This study will enable researchers to learn more about risk factors associated with the development of the disease. It will also offer participants additional testing and provide close monitoring every six months to monitor for the early detection of type 1 diabetes. Early detection may improve blood glucose control and reduce the chance of developing diabetes-related complications.
If you are interested in finding out more about this world-leading research and potentially participating in the trial, please visit www.diabetestrials.org or contact:
Christen Perry
Clinical Trials Manager
Tel: 03 9342 7063
Christen.perry@mh.org.au
TRIGR Trial
TRIGR is a global research study to find out if there is a connection between diet in infancy and the development of type 1 diabetes - and whether modifying the infant's diet can prevent or reduce the incidence of diabetes in children shown to be genetically at risk.
The rationale for TRIGR began with observational studies that showed that breastfeeding was associated with somewhat lower rates of children developing type 1 diabetes.
Recruitment for TRIGR has been completed. There are now 101 eligible babies being followed in Australia and 2162 internationally. For more information please see the TRIGR website
Prevention of Kidney Disease
Professor Mark Cooper from the Baker IDI Heart and Diabetes Institute in Melbourne, is conducting a clinical trial of a new medication which may be beneficial to people with type 1 diabetes and evidence of early kidney damage. If you have type 1 diabetes, early kidney damage but no other serious medical problems and are aged between 18 and 65 please contact the staff at The Centre for Clinical Studies at the Alfred Hospital on 1800 243 733 if you are interested in participating in the study. They will direct you to your closest clinical study site.